Official UK procurement notice
High resolution, in situ platform to combine single-cell and spatial genomics analyses.
Authority: UNIVERSITY OF MANCHESTER (Education)
What is being bought
Published requirement descriptionThe high resolution, in situ platform to combine single-cell and spatial genomics analyses, is required by the Genomic Technologies Core Facility (GTCF). Enabling multiplexed, error-robust, single-cell in situ transcriptomic imaging from whole tissue to subcellular resolution.
CPV: Medical equipments · Medical equipments, pharmaceuticals and personal care products
The lotProcurement structure
single lot · no lot value publishedLot #1Research - Genomic Technologies Core Facility (GTCF)
Procedure terms & legal framework
From the official record- Procedure method
- Award procedure without prior publication of a call for competition
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded without competition
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Direct award (no call for competition)
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 14 Jun 2023, 10:52 BST
- Last source update
- 14 Jun 2023, 10:52 BST
- Authority reference
2023/2060/HRSP/AHKC/AS/KC/AH/JD- FTS notice number
2023/S 000-016817- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-03d602Find a Tender
- Why no open competition
- The procurement falls outside the scope of application of the directive
- Published justification
The High resolution in situ platform to combine single-cell and spatial genomics analyses, is required by the Genomic Technologies Core Facility
The High resolution in situ platform to combine single-cell and spatial genomics analyses is provided by Vizgen Inc., who are the sole provider of the MERSCOPE Platform. MERSCOPE is the
MERFISH technology platform solution developed by the supplier. The MERSCOPE Platform is powered by MERFISH (Multiplexed Error Robust in situ Hybridization) technology, which is exclusively licensed to Vizgen by Harvard University for commercialisation.
This solution enables multiplexed, error-robust, single-cell in situ transcriptomic imaging from whole tissue to subcellular resolution.
This product and it's use is covered by U.S. patents
- Review procedure
The Authority will incorporate a minimum 10 calendar day standstill period at the point of publication of this VEAT notice.
Note: A purchase order will not be raised until after the ten day notice of intention to contract.
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| Vizgen Inc. | £428,000 † | — | Awarded |
Contracts
High resolution, in situ platform to combine single-cell and spatial genomics analyses · Vizgen Inc.
- Signed
- 8 Jun 2023
- Value
- £428,000
- Status
- active
Contracting authority & participating public bodies
Dispute resolution & review bodies
- The High Court of Justice of EnglandReview body
Bidders & participating suppliers
1 commercial party on the notice- Vizgen Inc.Awarded supplier
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.